Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 497

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 497
---
 The Nasdaq Capital Market at the opening of business on March 14, 2024, and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on Nasdaq. The Company intends to timely request a hearing before the Panel to appeal the Notice received on March 5, 2024. A hearing request will stay the suspension of trading on the Company’s securities, and the Company’s securities will continue to trade on The Nasdaq Capital Market until the hearing process concludes and the Panel issues a written decision. The Company submitted a request for a hearing with Nasdaq to appeal the delisting determination on March 12, 2024 and have a hearing date of May 9, 2024. There can be no assurance that the Panel will grant the Company’s request for a suspension of delisting or continued listing on The Nasdaq Capital Market. On March 7, 2024, the Company filed with the Secretary of State of the State of Delaware an amendment to the Company’s amended and restated certificate of incorporation to change the date by which the Company must consummate a business combination to June 9, 2024. On March 7, 2024 at a special meeting of stockholders of the Company, stockholders holding 119,572 shares properly exercised their right to redeem their shares (and did not withdraw their redemption) for cash at a redemption price of approximately $10.58 per share, adjusted for applicable taxes in the amount of

F-51

TABLE OF CONTENTS

### IRIS ACQUISITION CORP

### NOTES TO FINANCIAL STATEMENTS
$60,000 taxes, including, but not limited to, franchise tax, excise tax and income tax. Following such redemptions, approximately $1,265,669 will be left in trust, subject to adjustment for applicable taxes, including, but not limited to, franchise tax, excise tax and income tax and 7,187,037 shares will remain outstanding.

Subsequent to December 31, 2023, the Company disbursed extension payments to the trust account totaling $45,684.

On March 9, 2024, the parties to the Business Combination Agreement, amended the Business Combination Agreement, PIPE Equity Subscription Agreement, and Convertible Note Subscription Agreement to extend the termination of these agreements to July 31, 2024.

On March 11, 2024, the Company entered into an administrative support agreement